Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 3Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Nonsquamous Non-small Cell Lung Cancer 1Non-Small Cell Lung Cancer Metastatic 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 1patritumab deruxtecan 1Platinum Compounds 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nonsquamous Non-small Cell Lung Cancer × patritumab deruxtecan × Thoracic × Clear all
NCT05338970 2025-01-31

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Daiichi Sankyo

Phase 3 Active not recruiting
586 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡